Manufacturing of GM1 gene therapy candidate PBGM01 from a dedicated suite at CDMO Catalent will begin by the end of the of the year, says Passage Bio. In July 2019, Passage Bio announced it had contracted Paragon Bioservices – fresh from its $1.2 billion acquisition by Catalent – to build a dedicated suite at its Harmans, Maryland facility to produce its AAV-delivered gene therapies for its monogenic central nervous system diseases; specifically GM1 gangliosidosis. GM1 is a rare monogenic recessive…
